Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure.

Seferovi´c, Petar M.; Gabriele, Fragasso; Mark, Petrie; Wilfried, Mullens; Roberto, Ferrari; Thomas, Thum; Johann, Bauersachs; Anker, Stefan D.; Robin, Ray; Yuksel, Çavu¸so˘glu; Marija, Polovina; Marco, Metra; Giuseppe, Ambrosio; Krishna, Prasad; Jelena, Seferovi´c; Jhund, Pardeep S.; Dattilo, Giuseppe; Jelena Cˇ elutkiene,; Massimo, Piepoli; Brenda, Moura; Ovidiu, Chioncel; Tuvia Ben Gal,; Stephane, Heymans; Tiny, Jaarsma; Loreena, Hill; Yuri, Lopatin; Lyon, Alexander R.; Piotr, Ponikowski; Mitja, Lainšˇcak; Ewa, Jankowska; Christian, Mueller; Francesco, Cosentino; Lund, Lars H.; Filippatos, Gerasimos S.; Frank, Ruschitzka; Coats, Andrew J. S.; Giuseppe, M. C. Rosano.

doi:10.1002/ejhf.2026.

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2diabetes mellitus.

Titolo:	Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure.
Autori:	Petar M. Seferovi´c (Primo) Gabriele Fragasso Mark Petrie Wilfried Mullens Roberto Ferrari Thomas Thum Johann Bauersachs Stefan D. Anker Robin Ray Yuksel Çavu¸so˘glu Marija Polovina Marco Metra Giuseppe Ambrosio Krishna Prasad Jelena Seferovi´c Pardeep S. Jhund DATTILO, Giuseppe Jelena Cˇ elutkiene Massimo Piepoli Brenda Moura Ovidiu Chioncel Tuvia Ben Gal Stephane Heymans Tiny Jaarsma Loreena Hill Yuri Lopatin Alexander R. Lyon Piotr Ponikowski Mitja Lainšˇcak Ewa Jankowska Christian Mueller Francesco Cosentino Lars H. Lund Gerasimos S. Filippatos Frank Ruschitzka Andrew J. S. Coats Giuseppe M. C. Rosano. (Ultimo) mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2020
Rivista:	EUROPEAN JOURNAL OF HEART FAILURE
Abstract:	The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2diabetes mellitus.
Handle:	http://hdl.handle.net/11570/3181442
Appare nelle tipologie:	14.a.1 Articolo su rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: